Role of dopamine transporter imaging in routine clinical practice

Movement Disorders

Volumn 18, Issue 12, 2003, Pages 1415-1423

  Marshall, Vicky ^a   Grosset, Donald ^a  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

Author keywords

Diagnosis; Dopamine transporter; Emission computed; Essential tremor; Parkinson's disease; Tomography

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ANTIEMETIC AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; TECHNETIUM 99M;

ALZHEIMER DISEASE; BASAL GANGLION; BRADYKINESIA; BRAIN INFARCTION; CLINICAL PRACTICE; CLINICAL TRIAL; CORPUS STRIATUM; DEMENTIA; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DYSTONIA; ESSENTIAL TREMOR; HUMAN; LEWY BODY; MUSCLE RIGIDITY; NERVE DEGENERATION; ONSET AGE; PARKINSONISM; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BRAIN; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ESSENTIAL TREMOR; HUMANS; IODINE RADIOISOTOPES; LEWY BODY DISEASE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TROPANES;

EID: 0345770368     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10592     Document Type: Review

References (84)

1. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
2. Fearnley JM Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990;113(Pt 6):1823-1842.
3. Hughes AJ, Ben Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 2001;57:S34-S38.
4. Hughes AJ, Daniel SE, Ben Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
5. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28: 99-102.
6. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726.
7. Kaufman MJ Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-49.
8. Niznik HB, Fogel EF, Fassos FF, et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198.
9. Jaber M, Jones S, Giros B, et al. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997;12:629-633.
10. Mozley PD, Schneider JS, Acton PD, et al. Binding of [99mTc-]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000;41: 584-589.
11. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
12. Kim HJ, Im JH, Yang SO, et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997;38:1703-1711.
13. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
14. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996; 37:1129-1133.
15. Kao P-F, Tzen K-Y, Yen T-C, et al. The optimal imaging time for [99mTc]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease. Nucl Med Commun 2001;22:151-154.
16. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
17. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-1884.
18. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997;38:1453-1459.
19. Innis RB, Marek K, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123 I] beta-CIT. Mov Disord 1999;14:436-442.
20. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
21. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.
22. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47:493-503.
23. 123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001;16:124-130.
24. 123I]beta-CIT SPECT. J Neurol 1998;245:14-20.
25. 123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
26. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50: 34-41.
27. Benamer HT, Patterson J, Wyper DJ, et al. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-698.
28. 123 I]&rtf-space;β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
29. Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123 I] FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27:867-869.
30. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
31. 123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 2001;108: 1011-1019.
32. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17:45-53.
33. 123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-1228.
34. 123I]-FP-CIT study group. Mov Disord 2000;15:503-510.
35. Marek K, Seibyl J, Holloway R, et al. A multicentre assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000;55:1540-1547.
36. Rajput AH, Rozdilsky B, Ang L, et al. Clinicopathologic observations in essential tremor: report of six cases. Neurology 1991; 41:1422-1424.
37. Marek K. Pramipexole versus Levodopa in the CALM-PD CIT study: effects on Parkinson's disease progression assessed by dopamine transporter imaging. Parkinson Study Group. Presentation EFNS Vienna 2002.
38. Fahn S. Results of the ELLDOPA (earlier vs. later levodopa) study. Presentation at Seventh International Congress of Parkinson's Disease and Movement Disorders, Miami, Florida 2002.
39. Jennings D, Seibyl J, Marek K. β-CIT SPECT versus clinical examination in parkinsonian syndrome: unmasking and early diagnosis [abstract]. Mov Disord 2002;17:1108.
40. Lee MS, Kim YD, Im JH, et al. 123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology 1999;52: 1422-1426.
41. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-272.
42. 123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9-24.
43. 123 I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-1032.
44. 123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167.
45. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-312.
46. Dresel SH, Kung MP, Huang XF, et al. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. J Nucl Med 1999;40:660-666.
47. Winikates J Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
48. Daniel SE Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39: 165-172.
49. Tzen KY, Lu CS, Yen TC, et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 2001;42:408-413.
50. 123I]B-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-523.
51. Stevens T, Livingston G, Kitchen G, et al. Islington study of dementia subtypes in the community. Br J Psychiatry 2002;180: 270-276.
52. McKeith IG, Fairbairn AF, Perry RH, et al. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994;165:324-332.
53. Ala TA, Yang KH, Sung JH, et al. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16-21.
54. Swanberg MM Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Safety 2002;25: 511-523.
55. Ditter SM Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754-760.
56. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
57. McKeith IGM, Galasko DM, Kosaka KM, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
58. McKeith IGM, Ballard CGM, Perry RHM, et al. Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.
59. Bowler JV, Munoz DG, Merskey H, et al. Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998;64:18-24.
60. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-1468.
61. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73: 134-140.
62. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24:320-325.
63. Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002;58:1489-1493.
64. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16:278-282.
65. Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994;8:293-306.
66. Stephen PJ Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
67. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 1999;19:322-328.
68. Masso MJF, Carrera N, Urtasun M, et al. Drugs inducing parkinsonism in our environment. J Neurol Neurosurg Psychiatry 1991; 54:1025.
69. Rajput AH, Rozdilsky B, Hornykiewicz O, et al. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 1982;39:644-646.
70. Chabolla DR, Maraganore DM, Ahlskog JE, et al. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998;73:724-727.
71. Friedman JH, Jennings D, Seibyl J, et al. β-CIT SPECT Imaging to distinguish drug-induced parkinsonism from idiopathic Parkinson's disease exacerbated by drugs: pilot data. Part 1. Mov Disord 2002;17:1108.
72. Lavalaye J, Linszen DH, Booij J, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 2001;47:59-67.
73. Booij J, Rijk-van Andel PJ, Noorden RA. No loss of striatal dopamine transporters and D2 receptors in patients with autosomal recessive dopa-responsive dystonia. J Nucl Med 1999;40:67.
74. 123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792-800.
75. 123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 1997;12:448-451.
76. Koller WC, Lang A, Vetere-Overfield RN, et al. Psychogenic tremors. Neurology 1989;39:1094-1099.
77. O'Sullivan JD, Costa DC, Lees AJ. Confirming Parkinson's disease with 123I FP-CIT SPECT (abstract). Eur J Neurol 1999;6: 131.
78. 123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-64.
79. Yen TC, Lu CS, Tzen KY, et al. Decreased dopamine transporter binding in Machado-Joseph disease. J Nucl Med 2000;41:994-998.
80. Borasio GD, Linke R, Schwarz J, et al. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry 1998;65:263-265.
81. 123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-1361.
82. Naumann M, Pirker W, Reiners K, et al. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 1998;13:319-323.
83. Tolosa E Catafau AM. Clinical Impact of performing SPECT imaging with the dopamine transporter imaging agent 123 I-ioflupane (DaTSCAN) in patients with a clinically uncertain diagnosis of parkinsonian syndromes (abstract). Eur J Neurol 2002;9:27.
84. Løkkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med 2002;29:1623-1629.